B2BROKER
25.1.2022 13:02:11 CET | Business Wire | Press release
B2Broker , a leading liquidity and technology provider of solutions to the Forex and financial services industry, has secured a licence from the Financial Services Commission (FSC) Mauritius , the company has announced. The licence has been acquired under the name of B2B Prime Services Limited, a member of the B2Broker Group of Companies, which as of 12th November, 2021, possesses an Investment Dealer licence (Full Service Dealer excluding underwriting /code SEC-2.1, Licence # C117017139).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005241/en/
Description of Authorised Activity
As an authorised Dealer in Securities, B2B Prime Services is permitted to act as intermediary in the execution of securities transactions for clients in accordance with the country’s local legislation. Under Mauritius regulation, the company will operate as a Prime of Prime (PoP) Multi-Asset Liquidity Provider, focusing on institutional and professional clients across the whole spectrum of the financial markets. Its core investment services consist of leveraged derivative products in CFDs (e.g. Forex, metals, commodities, shares, indices).
About the FSC
The FSC is the integrated regulator in Mauritius for the financial services sector and was established in 2001 to licence, regulate, monitor and supervise the conduct of business activities in these sectors in accordance with local legislation. The regulator is committed to the sustained development of Mauritius as a sound and competitive Financial Services Centre with the aim of promoting the development, fairness, efficiency and transparency of financial institutions and capital markets, suppressing crime and malpractices so as to provide protection to members of the public investing in non-banking financial products, and ensuring the soundness and stability of the financial system in Mauritius.
About B2Broker Group of Companies
B2Broker is a global brand with a solid reputation in the B2B sphere as one of the most in-demand technology and liquidity providers for Forex and crypto brokers, crypto exchanges and other financial services entities. The group helps these firms empower their businesses through building a successful, transparent and ethical environment and connecting them to the markets in a short space of time and at a reasonable cost.
B2Broker offers a broad range of services including Crypto/Forex/CFD liquidity, Crypto/Forex Broker turnkey solutions, crypto payment processing (B2BinPay), MT4/5 white label solutions, B2Core (Trader’s Room) , B2Trader (Matching Engine) and liquidity on over 800 trading instruments across the entire spectrum of assets.
Headquartered in Moscow, B2Broker has several years of operational experience with 10 offices in 8 countries across Russia, Europe, Asia and MENA. A total of 7 licences so far to its name including FCA, AEMI, Central Bank of Russia, and now FSC, allows B2Broker to serve clients across more than 50 countries, offering Forex liquidity distribution and a range of other services to the Forex, Crypto and Securities industries. The company has secured a large portfolio of well-known global clients in the financial services industry with plans to further increase company representation and visibility across the globe.
CEO and Founder of B2Broker Group, Arthur Azizov, commented, “We are pleased to have added another prestigious licence to our growing portfolio. The licence ensures the reliability and transparency of all operations in accordance with the strict supervision of the FSC and adds further credibility to us as a leading global fintech player. Industry regulation is undoubtedly the best way to achieve total legitimisation of the Forex and financial services industry and our latest licence acquisition means that even more clients across the world will be able to benefit from the highest level of protection offered by one of the world’s leading, multi-regulated technology and liquidity providers.”
The acquisition of the latest FSC licence broadens B2Broker’s horizons enabling the company to secure further business in its quest to expand its global reach. Aside from this latest licence acquisition, the company currently has several other licence applications with established regulators in process which are expected to be concluded during 2022.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom